CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alexza Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alexza Pharmaceuticals, Inc.
2091 Stierlin Ct
Phone: (650) 944-7000p:650 944-7000 MOUNTAIN VIEW, CA  94043-4655  United States Fax: (650) 944-7999f:650 944-7999

This company was Merged or Acquired on 6/21/2016.
This company ceased filing statements with the SEC on 7/15/2016.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201612/31/2015YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Principal Financial Officer & Principal Accounting Officer, Dir Tom B.King 60 10/16/2015 6/1/2003
Executive Vice President - R&D and Quality Edwin S.Kamemoto 61 4/28/2015 6/27/2014
Vice President - Pharmaceutical R&D & Quality Lori H.Takahashi 4/29/2015 4/29/2015
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Alexza UK Limited
Atlas U.S. Royalty, LLC
Symphony Allegro, Inc.

General Information
Stock Exchange: OTC
Federal Tax Id: 770567768
Fax Number: (650) 944-7999


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023